Isoprenaline

Newborn use only

| Alert | Also known as Isoproterenol. | | |
|--------------------------------|--|---|--|
| Indication | · | arrhythmia or heart block especially if caused by beta blocker | |
| | overdose. | | |
| Action | β ₁ - and β ₂ -adrenoceptor agonist. Its action on cardiac β ₁ -adrenoceptors results in positive inotropic and | | |
| | chronotropic effects on the heart elevating blood pressure. Its action on arteriolar β_2 -adrenoceptors | | |
| | 1 | olic blood pressure. The overall effect is to decrease mean | |
| | arterial pressure due to the β_2 -adrenoceptor mediated vasodilation. [1] | | |
| Drug type | Catecholamine, β-adrenoceptor agonist drug | | |
| Trade name | Isuprel Marie - Jeanne die Huderchleride Care (v.) (CAC and dest) | | |
| Presentation | Monico - Isoprenaline Hydrochloride 0.2mg/ | mL (SAS product) | |
| Dose | 1 mg/5 mL ampoule = 200 microgram/1 mL. | | |
| Dose | 0.05–1 microgram/kg/minute. | | |
| | Doses may need to be many times higher in the management of beta blocker overdose. Consult with a clinical toxicologist (Poisons Information Centre 131126). | | |
| Dose adjustment | community of the commun | | |
| Maximum dose | 2 microgram/kg/minute. | | |
| | | nt of B-blocker overdose. Consult with a clinical toxicologist | |
| | (Poisons Information Centre 131126). | | |
| Total cumulative | | | |
| dose | | | |
| Route | IV infusion. | | |
| Preparation | LOW concentration IV infusion | | |
| | Infusion strength | Prescribed amount | |
| | 1 mL/hour = 0.05 microgram/kg/minute | 150 microgram/kg isoprenaline and make up to 50 mL | |
| | | prenaline and add glucose 5% or sodium chloride 0.9% to | |
| | make a final volume of 50 mL. Infusing at a r | ate of 1 mL/hour = 0.05 microgram/kg/minute. | |
| | IIICII aanaantustian IV infusion (aan ha waa | d fau infanta un ta 2.4 kg | |
| | HIGH concentration IV infusion (can be used Infusion strength | Prescribed amount | |
| | 1 mL/hour = 0.5 microgram/kg/minute | 1500 microgram/kg isoprenaline and make up to 50 mL | |
| | | soprenaline and add glucose 5% or sodium chloride 0.9% to | |
| | | ate of 1 mL/hour = 0.5 microgram/kg/minute. | |
| | | | |
| | *Maximum reported concentration of the in | nfusion preparation is 64 microgram/mL.(12) | |
| Administration | | | |
| | Change infusion every 24 hours. | | |
| Monitoring | Continuous heart rate, ECG and blood pressure monitoring preferable. | | |
| J | Continuous heart rate, ECG and blood pressu | ure monitoring preferable. | |
| J | Assess urine output and peripheral perfusion | <u> </u> | |
| | Assess urine output and peripheral perfusion Blood glucose. | n frequently. | |
| Contraindications | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc | h frequently. k caused by digitalis intoxication; ventricular arrhythmias | |
| | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. | |
| | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo | h frequently. k caused by digitalis intoxication; ventricular arrhythmias | |
| Contraindications | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. usly with adrenaline because their combined effects may | |
| | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. Isoprenaline infusion may produce an increa | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. | |
| Contraindications | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. Isoprenaline infusion may produce an increa Titrate drug dose to heart rate. | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. usly with adrenaline because their combined effects may | |
| Contraindications | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. Isoprenaline infusion may produce an increa Titrate drug dose to heart rate. Correct acidosis prior to commencement. | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. usly with adrenaline because their combined effects may se in myocardial work and oxygen consumption. | |
| Contraindications | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. Isoprenaline infusion may produce an increa Titrate drug dose to heart rate. Correct acidosis prior to commencement. Ensure adequate circulating blood volume p | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. usly with adrenaline because their combined effects may see in myocardial work and oxygen consumption. | |
| Contraindications | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. Isoprenaline infusion may produce an increa Titrate drug dose to heart rate. Correct acidosis prior to commencement. | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. usly with adrenaline because their combined effects may see in myocardial work and oxygen consumption. | |
| Contraindications | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. Isoprenaline infusion may produce an increa Titrate drug dose to heart rate. Correct acidosis prior to commencement. Ensure adequate circulating blood volume pradditional volume expansion may be require | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. usly with adrenaline because their combined effects may see in myocardial work and oxygen consumption. | |
| Contraindications Precautions | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. Isoprenaline infusion may produce an increa Titrate drug dose to heart rate. Correct acidosis prior to commencement. Ensure adequate circulating blood volume padditional volume expansion may be require Stimulates insulin secretion. Inhalational anaesthetics can increase the effective of the serious stimulates insulin secretion. | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. usly with adrenaline because their combined effects may see in myocardial work and oxygen consumption. | |
| Contraindications Precautions | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. Isoprenaline infusion may produce an increa Titrate drug dose to heart rate. Correct acidosis prior to commencement. Ensure adequate circulating blood volume padditional volume expansion may be require Stimulates insulin secretion. Inhalational anaesthetics can increase the effective of the serious stimulates insulin secretion. | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. usly with adrenaline because their combined effects may see in myocardial work and oxygen consumption. rior to commencement. As isoprenaline is a vasodilator, and during infusion. | |
| Contraindications Precautions | Assess urine output and peripheral perfusion Blood glucose. Tachyarrhythmias; tachycardia or heart bloc which require inotropic therapy; coronary in Isoprenaline should not be given simultaneo induce serious arrhythmia. Isoprenaline infusion may produce an increat Titrate drug dose to heart rate. Correct acidosis prior to commencement. Ensure adequate circulating blood volume pradditional volume expansion may be required Stimulates insulin secretion. Inhalational anaesthetics can increase the effuse of isoprenaline hydrochloride in conjunction. | k caused by digitalis intoxication; ventricular arrhythmias sufficiency; hypersensitivity to isoprenaline. usly with adrenaline because their combined effects may see in myocardial work and oxygen consumption. rior to commencement. As isoprenaline is a vasodilator, and during infusion. | |

ANMF consensus group JHCH_NICU_19.086

Isoprenaline

Page 1 of 3

Isoprenaline

Newborn use only

| | Counting a purposition |
|------------------|--|
| | Cardiac arrhythmias. |
| | Systemic vasodilation and hypotension. |
| | Hypoglycaemia. |
| Compatibility | Extravasation (12) Fluids (14): Glucose 5%; sodium chloride 0.9%. |
| Compatibility | Y-site (12,14): Aciclovir, adrenaline (epinephrine), amikacin, amiodarone, amphotericin B liposomal, |
| | atracurium, atropine, azithromycin, aztreonam, benzylpenicillin, calcium chloride, calcium gluconate, |
| | cefazolin, cefotaxime, ceftazidime, ceftriaxone, chloramphenicol, clindamycin, dexamethasone, digoxin, |
| | dobutamine, dopamine, erythromycin, fentanyl, fluconazole, gentamicin, heparin, hydrocortisone, |
| | lidocaine (lignocaine), linezolid, magnesium sulfate, metronidazole, milrinone, morphine, nitroprusside, |
| | nitroglycerin, noradrenaline (norepinephrine), pamidronate, pancuronium, piperacillin-tazobactam, |
| | potassium acetate, potassium chloride, propofol, ranitidine, remifentanil, ticarcillin-clavulanate, |
| | vancomycin, vasopressin, vitamin K. |
| ncompatibility | Aminophylline, ampicillin sodium, amphotericin B conventional colloidal, amphotericin B lipid complex, , |
| . , | diazepam, diazoxide, furosemide, ganciclovir, hydralazine, ibuprofen, indomethacin, insulin, pantoprazole, |
| | phenobarbitone (phenobarbital), phenytoin, sodium bicarbonate, sulfamethoxazole-trimethoprim. |
| Stability | Do not administer if the solution is pinkish or darker than slightly yellow or if a precipitate is present. |
| • | Change the infusion every 24 hours. |
| Storage | Store below 25°C. Protect from light. |
| Excipients | Disodium edetate, sodium citrate dihydrate, citric acid, sodium chloride, hydrochloride acid or sodium |
| | hydroxide. |
| | |
| | Monico - Isoprenaline Hydrochloride: sodium metabisulphite and water for injections. |
| Special comments | |
| Evidence | Efficacy: |
| | The efficacy and dosing of isoprenaline in newborns has only been assessed in case reports. |
| | Infants with congenital complete heart block: Case reports of response to isoprenaline infusion in |
| | newborns with congenital heart block.[2-4] (LOE IV, GOR D) |
| | The European Society of Cardiology Guidelines recommend for patients with bradyarrhythmia, positive |
| | chronotropic drug infusion (e.g. isoprenaline, adrenaline (epinephrine), etc.) may be preferred for a |
| | limited time, unless there is a contra-indication, compared to use of a temporary pacemaker. [5] |
| | There are insufficient data reported to determine its safety or efficacy in newborns with pulmonary |
| | hypertension. |
| | Safety: |
| | Case reports of arrhythmia/tachycardia [6] [4], elevated serum CPK-MB levels [7] and hypotension.[8] In |
| | animal studies, use of isoprenaline hydrochloride in conjunction with aminophylline and corticosteroids |
| | have been shown to be additive in cardiotoxic properties and can lead to myocardial necrosis and |
| | death.[11] Pharmacokinetics: |
| | In children age 2 days to 14 years, average plasma half-life 4.2 ± 1.5 minutes, with linear relationship |
| | between steady state concentration and dosing rate.[10] |
| Practice points | between steady state concentration and dosing rate.[10] |
| References | Noori S, Seri I. Neonatal blood pressure support: the use of inotropes, lusitropes, and other |
| | vasopressor agents. Clinics in perinatology. 2012;39:221-38. |
| | 2. Deloof E, Devlieger H, Van Hoestenberghe R, Van den berghe K, Daenen W, Gewillig M. Management |
| | with a staged approach of the premature hydropic fetus due to complete congenital heart block. |
| | European Journal of Pediatrics. 1997;156:521-3. |
| | |
| | 3. Glatz AC, Gaynor JW, Rhodes LA, Rychik J, Tanel RE, Vetter VL, Kaltman JR, Nicolson SC, Montenegro L, |
| | 3. Glatz AC, Gaynor JW, Rhodes LA, Rychik J, Tanel RE, Vetter VL, Kaltman JR, Nicolson SC, Montenegro L, Shah MJ. Outcome of high-risk neonates with congenital complete heart block paced in the first 24 |
| | |
| | Shah MJ. Outcome of high-risk neonates with congenital complete heart block paced in the first 24 |
| | Shah MJ. Outcome of high-risk neonates with congenital complete heart block paced in the first 24 hours after birth. The Journal of thoracic and cardiovascular surgery. 2008;136:767-73. |

ANMF consensus group Isoprenaline Page 2 of 3
JHCH_NICU_19.086

Isoprenaline

Newborn use only

- 5. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). European heart journal. 2013;34:2281-329.
- 6. Steiner P, Rao M, Ehrlich R, Padre R. The use of intravenous isoproterenol in the treatment of status asthmaticus. The Journal of asthma research. 1975;12:215-9.
- 7. Maguire JF, Geha RS, Umetsu DT. Myocardial specific creatine phosphokinase isoenzyme elevation in children with asthma treated with intravenous isoproterenol. The Journal of allergy and clinical immunology. 1986;78:631-6.
- 8. Kussman BD, Madril DR, Thiagarajan RR, Walsh EP, Laussen PC. Anesthetic management of the neonate with congenital complete heart block: a 16-year review. Paediatric anaesthesia. 2005;15:1059-66.
- 9. Reyes G, Schwartz PH, Newth CJ, Eldadah MK. The pharmacokinetics of isoproterenol in critically ill pediatric patients. Journal of clinical pharmacology. 1993;33:29-34.
- 10. Vick J, Joseph X, Whitehurst V, Herman E, Balazs T. Cardiotoxic effects of the combined use of caffeine and isoproterenol in the minipig. J Toxicol Environ Health. 1989;26(4):425-35.
- 11. Merative[™] Micromedex® Complete IV Compatibility (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 25th July 2023).

| VERSION/NUMBER | DATE |
|----------------------------|------------|
| Original 1.0 | 6/10/2016 |
| Version 2.0 | 17/05/2021 |
| Version 2.0 (Minor errata) | 25/07/2023 |
| REVIEW | 17/05/2026 |

Authors Contribution

| Original author/s | David Osborn, Srinivas Bolisetty |
|-------------------------|---|
| Evidence Review | David Osborn |
| Expert review | Hiroko Asakai |
| Nursing Review | Eszter Jozsa, Kirsty Minter |
| Pharmacy Review | Thao Tran, Cindy Chen, Mohammad Irfan Azeem |
| ANMF Group contributors | Nilkant Phad, Bhavesh Mehta, John Sinn, Michelle Jenkins, Jessica Mehegan, Helen Huynh, |
| | Simarjit Kaur |
| Final editing | Mohammad Irfan Azeem |
| Electronic version | Cindy Chen, Ian Callander |
| Facilitator | Srinivas Bolisetty |
| | |